We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Quest Diagnostics Inks Lab Service Deal With ReproSource
Read MoreHide Full Article
Quest Diagnostics Incorporated (DGX - Free Report) has been making headlines on a slew of strategic developments. Following the company’s purchase of aspecialty fertility diagnostic services provider ReproSource, earlier this week, the company has again come up with a new laboratory partnership.
This time, Quest Diagnostics has formed an alliance with Regional Medical Center Health System (RMC), a regional health care provider for a five-county service area in northeast Alabama. RMC currently has 323 inpatient beds at RMC Anniston and 125 acute care beds at Stringfellow Memorial Hospital.
This apart, it has numerous outpatient facilities and physician offices. RMC is currently the largest not-for-profit healthcare provider in Northeast Alabama. The partnership aims at improving Quest Diagnostics’ supply chain efficiency. However, financial terms of the deal remained undisclosed.
Apart from providing supply chain expertise, Quest Diagnostics will also perform laboratory reference testing. More specifically, the company will manage laboratory equipment, supplies and procurement processes for RMC and Stringfellow Memorial Hospital in Anniston, AL, along with providing reference testing for both hospitals. This integration is expected to enhance the quality and value of diagnostic services.
Notably, this development remains aligned with the second element of Quest Diagnostics’ growth acceleration strategy that underlines the company’sinclination toward consistent extension of health plan contracts and tie-ups with hospital health systems.In this regard, the company recently signed an expanded partnership agreement with UnitedHealthcare. This alliance will be active from January 2019 onward under which, Quest Diagnostics will be participating as a national provider of laboratory services for all UnitedHealthcare plan participants.
Share Price Performance
Shares of Quest Diagnostics have underperformed its industry over the past three months. The stock has lost 2.5% versus the industry's 6% rise.
Zacks Rank & Key Picks
Quest Diagnostics currently carries a Zacks Rank #3 (Buy). Some better-ranked stocks in the broader medical space are Intuitive Surgical (ISRG - Free Report) , Amedisys, Inc. (AMED - Free Report) and Masimo Corporation (MASI - Free Report) .
Intuitive Surgical’s expected long-term earnings growth rate is 14.7%. The stock currently carries a Zacks Rank #2 (Buy).
Masimo’s projected long-term earnings growth rate is 14.8%. The stock has a Zacks Rank of 2 at present.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Quest Diagnostics Inks Lab Service Deal With ReproSource
Quest Diagnostics Incorporated (DGX - Free Report) has been making headlines on a slew of strategic developments. Following the company’s purchase of aspecialty fertility diagnostic services provider ReproSource, earlier this week, the company has again come up with a new laboratory partnership.
This time, Quest Diagnostics has formed an alliance with Regional Medical Center Health System (RMC), a regional health care provider for a five-county service area in northeast Alabama. RMC currently has 323 inpatient beds at RMC Anniston and 125 acute care beds at Stringfellow Memorial Hospital.
This apart, it has numerous outpatient facilities and physician offices. RMC is currently the largest not-for-profit healthcare provider in Northeast Alabama. The partnership aims at improving Quest Diagnostics’ supply chain efficiency. However, financial terms of the deal remained undisclosed.
Apart from providing supply chain expertise, Quest Diagnostics will also perform laboratory reference testing. More specifically, the company will manage laboratory equipment, supplies and procurement processes for RMC and Stringfellow Memorial Hospital in Anniston, AL, along with providing reference testing for both hospitals. This integration is expected to enhance the quality and value of diagnostic services.
Notably, this development remains aligned with the second element of Quest Diagnostics’ growth acceleration strategy that underlines the company’sinclination toward consistent extension of health plan contracts and tie-ups with hospital health systems.In this regard, the company recently signed an expanded partnership agreement with UnitedHealthcare. This alliance will be active from January 2019 onward under which, Quest Diagnostics will be participating as a national provider of laboratory services for all UnitedHealthcare plan participants.
Share Price Performance
Shares of Quest Diagnostics have underperformed its industry over the past three months. The stock has lost 2.5% versus the industry's 6% rise.
Zacks Rank & Key Picks
Quest Diagnostics currently carries a Zacks Rank #3 (Buy). Some better-ranked stocks in the broader medical space are Intuitive Surgical (ISRG - Free Report) , Amedisys, Inc. (AMED - Free Report) and Masimo Corporation (MASI - Free Report) .
Intuitive Surgical’s expected long-term earnings growth rate is 14.7%. The stock currently carries a Zacks Rank #2 (Buy).
Amedisys’ estimated long-term earnings growth rate is 19.4%. The stock sports a Zacks Rank #1 (Strong Buy) at the moment. You can see the complete list of today’s Zacks #1 Rank stocks here.
Masimo’s projected long-term earnings growth rate is 14.8%. The stock has a Zacks Rank of 2 at present.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>